Bopindolol is a nonselective beta-adrenoceptor antagonist [corrected] with partial agonist activity which is used in the treatment of hypertension. The drug is rapidly metabolised to an active hydrolysed form. The antihypertensive effects of bopindolol 0.5 to 4 mg are sustained for more than 24 hours after once daily dosing, and the drug appears similar in efficacy to propranolol, metoprolol, atenolol, pindolol and slow release nifedipine in the treatment of mild to moderate forms of this disease. In limited trials bopindolol has also successfully reduced symptoms in patients with angina pectoris, anxiety and essential tremor. Thus, bopindolol is an effective and well-tolerated beta-adrenoceptor antagonist.

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199141010-00010DOI Listing

Publication Analysis

Top Keywords

beta-adrenoceptor antagonist
8
bopindolol
5
bopindolol review
4
review pharmacodynamic
4
pharmacodynamic pharmacokinetic
4
pharmacokinetic properties
4
properties therapeutic
4
therapeutic efficacy
4
efficacy bopindolol
4
bopindolol nonselective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!